Tata Medical develops fast-testing solution for Covid-19


PTI, Dec 26, 2021, 9:18 AM IST

Source: unsplash

Tata Medical & Diagnostics on Wednesday said it has indigenously developed a fast-testing solution for Covid-19 to significantly boost India’s testing capacity amid the Omicron variant threat.

The solution, Tata MD CHECK Express RT-PCR, can be applied in multiple areas where quick, high volume, and reliable testing is required, such as airports and events, the company claimed.

With studies in India pointing to a possible surge in cases in February next year, there is expected to be a multifold increase in demand for RT-PCR Covid tests that are economical and give fast results, it added.

To meet this challenge, Tata Medical & Diagnostics (Tata MD) has indigenously developed the Covid testing solutions that will significantly boost India’s Covid testing capacity, the company said.

Its solutions include ‘Tata MD CHECK XF’, a kit that has a processing time of one hour and can process 30 samples per batch per machine. It is approved by ICMR with over 95 per cent sensitivity and 100 per cent specificity.

The other one is the ‘Tata MD CHECK RT-PCR Fast 3Gene’ kit that uses a fast amplification protocol, with a processing time of 90 minutes and can process 90 samples per batch per machine. It is approved by ICMR with 100 per cent sensitivity and 100 per cent specificity, the company said.

Tata Medical & Diagnostics CEO Girish Krishnamurthy said the company was striving to indigenously develop innovative medical technologies and working on several new technologies for Covid-19 testing.

“These express testing solutions can be applied in multiple areas where quick, high volume, and reliable testing is required such as airports and events,” he added.

The company said its new Tata MD CHECK Express PCR testing solution has been in use at the Kempegowda International Airport, Bengaluru, since early this month and has proven to deliver rapid and dependable results in a real-world environment with a high volume of tests.

“It has proved instrumental in helping to address the rush of fliers from ‘high risk’ countries required to undergo mandatory RT-PCR testing,” the company said.

Last year in November, the company had launched its Covid testing kit, ‘TataMD CHECK’, developed in partnership with CSIR-IGIB (Council of Scientific and Industrial Research-Institute of Genomics and Integrative Biology). It has been approved by the Indian Council of Medical Research and Drug Controller General of India (DCGI).

 

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

‘COVID was different’: SC bemoans distribution of free ration

Nagarjuna’s younger son Akhil Akkineni engaged

People getting heartburns after I became CM for second time: Siddaramaiah

Newborn baby kidnapped from Kalaburagi hospital in Karnataka

Gukesh draws with Liren in second game of World Chess Championship

All about ‘One Nation One Subscription’ scheme

PAN cards with QR code planned under PAN 2.0 project

Related Articles More

Genetic vulnerability for low insulin, unhealthy fat major causes for diabetes in South Asians: Study

Study links overthinking to ‘constant communication’ between brain’s fear-centre, social behaviour

Mangaluru: Campco opposes WHO’s claim of arecanut being carcinogenic

10 month baby gets new heart, new life

World COPD Day: Know your lung function

MUST WATCH

Grafting

Coconut Flower

Prakash Belawadi

Naxal Leader Vikram Gowda

Christmas Cake Fruit Mixing


Latest Additions

‘COVID was different’: SC bemoans distribution of free ration

Telugu actor Shri Tej booked for alleged cheating, false marriage promise

Five arrested in connection with botched angioplasty deaths at Gujarat hospital

Deceased Kannur official’s widow moves Kerala HC for CBI probe into his death

CAMPCO urges Centre to take action on areca nut ‘carcinogen classification’

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.